| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,195 |
9,144 |
$947K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
10,071 |
8,455 |
$580K |
| 99199 |
Unlisted special service, procedure or report |
86,727 |
51,723 |
$496K |
| 99215 |
Prolong outpt/office vis |
2,395 |
2,015 |
$299K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
2,289 |
1,756 |
$280K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,641 |
1,431 |
$131K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,447 |
1,265 |
$124K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
5,426 |
4,672 |
$100K |
| 99417 |
Prolong home eval add 15m |
545 |
452 |
$91K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,395 |
2,770 |
$91K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
2,513 |
2,160 |
$77K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,003 |
824 |
$76K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,652 |
1,316 |
$76K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,217 |
1,793 |
$75K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
6,172 |
5,349 |
$52K |
| D0145 |
Oral evaluation for a patient under three years of age |
1,338 |
1,192 |
$44K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
407 |
362 |
$38K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
511 |
213 |
$26K |
| 96127 |
|
3,824 |
2,542 |
$19K |
| D1206 |
Topical application of fluoride varnish |
1,250 |
1,141 |
$19K |
| 99401 |
|
1,015 |
735 |
$15K |
| 85018 |
|
3,797 |
3,217 |
$6K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
431 |
298 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
396 |
375 |
$5K |
| 99354 |
|
30 |
24 |
$4K |
| 90473 |
|
141 |
138 |
$3K |
| 87634 |
|
99 |
72 |
$3K |
| 90474 |
|
149 |
115 |
$3K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
121 |
92 |
$2K |
| 96160 |
|
532 |
422 |
$2K |
| 90686 |
|
1,079 |
974 |
$1K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
17 |
12 |
$1K |
| 0071A |
|
26 |
19 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
90 |
45 |
$1K |
| 92551 |
|
5,154 |
4,426 |
$1K |
| 96161 |
|
349 |
284 |
$1K |
| 99460 |
|
13 |
12 |
$1K |
| 0072A |
|
13 |
13 |
$881.72 |
| 90672 |
|
316 |
287 |
$737.52 |
| 99173 |
|
5,210 |
4,480 |
$662.01 |
| 90619 |
|
15 |
14 |
$152.40 |
| 81002 |
|
14 |
12 |
$36.41 |
| 90674 |
|
88 |
71 |
$30.00 |
| 94760 |
|
135 |
117 |
$19.43 |
| 90661 |
|
40 |
38 |
$0.02 |
| 90685 |
|
12 |
12 |
$0.00 |
| 90670 |
|
419 |
335 |
$0.00 |
| 3280F |
|
29 |
27 |
$0.00 |
| 90633 |
|
27 |
27 |
$0.00 |
| 99072 |
|
35 |
25 |
$0.00 |
| 2000F |
|
475 |
451 |
$0.00 |
| 3008F |
|
510 |
478 |
$0.00 |
| 90723 |
|
91 |
67 |
$0.00 |
| 90647 |
|
90 |
80 |
$0.00 |
| 90680 |
|
54 |
39 |
$0.00 |
| 91307 |
|
39 |
19 |
$0.00 |
| 90677 |
|
45 |
43 |
$0.00 |
| 99000 |
|
19 |
14 |
$0.00 |